EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,240 JPY | -0.30% |
|
+5.74% | -11.51% |
| 24/04 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
| 23/04 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 43.82 and 36.02 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.51% | 11.37B | A- | ||
| +26.03% | 661B | C+ | ||
| +26.74% | 566B | B | ||
| -6.66% | 352B | C+ | ||
| +19.35% | 332B | B- | ||
| +3.36% | 283B | C+ | ||
| +13.43% | 231B | B+ | ||
| +4.71% | 200B | B- | ||
| -9.53% | 195B | A+ | ||
| -4.23% | 145B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4523 Stock
- Ratings Eisai Co., Ltd.
